SMS Pharmaceuticals Q1 FY27: steady margins, filing momentum, and a capex-backed growth plan

SMS Pharmaceuticals opened FY27 with a steady quarter. Revenue from operations rose to INR 206.96 crore in Q1 FY27, up 6% from INR 196.05 crore a year ago. Operating profitability held firm. EBITDA came in at INR 40.95 crore, up 4% year on year, and EBITDA margin stayed around 20%. Profit after tax increased 8% year on year to INR 20.20 crore, translating into a PAT margin of about 10%.

The company’s message in the investor presentation was consistent: the base business is stable, margins have structurally improved over multiple cycles, and the next leg of growth is intended to come from a mix of high-volume scale-up, filing-led portfolio expansion, and a capex program that is nearing completion.

The quarter in numbers: YoY growth, QoQ softness

While year-on-year trends were positive, sequentially Q1 was softer. Revenue declined 13% quarter on quarter from INR 237.95 crore in Q4 FY26, and PAT was down 4% from INR 20.96 crore. Management did not provide a detailed operational bridge for the quarter-on-quarter change, but the overall margins held up, with Q1 FY27 EBITDA at INR 40.95 crore versus INR 39.90 crore in Q4 FY26.

At the gross profit line, the consolidated P and L shows gross profit of INR 74.93 crore and a gross margin of 36% for Q1 FY27. The presentation also discusses gross margin expansion across cycles using a different basis, described as gross margin excluding manufacturing expenses, and cites Q1 FY26 at 46%. Investors should read these as different definitions and not directly comparable.

Business profile: diversified APIs with regulated-market skew

SMS Pharmaceuticals positions itself as a diversified API player with a global presence and a strong footprint in regulated markets. The company states that 88% of revenue comes from regulated markets. It also highlights scale, vertical integration, and a strategic focus on R and D as core elements of its operating model.

The company reports over 55 APIs across 14 therapeutic segments, 120 plus DMFs filed till date, and operations spanning 75 plus countries. In FY26, its customer base included large pharma (59% of revenue) and mid-to-small pharma (41%). Customer concentration is meaningful but not extreme: the largest customer accounted for 28% of FY26 revenue, top 2 to 10 customers for 31%, and the remaining 41%.

On the manufacturing side, the presentation outlines two key sites.

Hyderabad is described as a niche small-volume facility with 120 KL capacity and approvals including USFDA, EUGMP, KFDA, CDSCO, and PMDA, with six USFDA approvals mentioned. Vizag is positioned as a niche large-volume plant with 3,000 KL capacity and approvals including USFDA, KFDA, CDSCO, and PMDA, with four USFDA approvals mentioned.

The company also references VKT Pharma as an associate, including historical milestones such as USFDA inspection success and an approval for reformulated ranitidine at the associate.

Mix and operating metrics: therapeutic and geographic spread

The presentation provides a therapeutic area revenue mix for FY26, split across high-volume and high-value categories. In FY26, ARV contributed 28% and anti-inflammatory 20% of revenue. High-value therapeutic segments included anti-diabetic at 15% and anti-migraine at 11%.

The FY26 therapeutic area revenue shares disclosed are:

For geography, the presentation provides FY26 revenue by location. Asia excluding India was the largest at 31%, followed by North America at 26% and Europe at 22%. EOU/SEZ/DE sales accounted for 15%, while India was 6%.

These splits underline a portfolio that is not dependent on a single region, though the company remains heavily exposed to regulated markets.

Strategy: filings, capex completion, and better asset turns

The forward strategy highlighted in the presentation has three clear pillars.

First is regulatory and product pipeline execution. The company stated it completed 4 DME/CEP filings in Q1 FY27 and is on track to meet a FY27 target of 10 DME/CEP filings. Beyond that near-term target, the company also set an objective of 20 DMF, CEP, and dossier filings over the next 24 months.

Second is investment in R and D and newer platforms. The presentation states R and D team strength increased to 200. It also states an intent to double R and D investment over the next 15 months. A key related development is the board-approved infusion of up to INR 50 crore as a loan into subsidiary SMS Peptides Private Limited. This follows an INR 8 crore investment in FY26 to establish a dedicated peptide R and D facility.

Third is capex-backed scale and improved utilisation. The company disclosed a total capex program of INR 280 crore, with 89% greenfield and 11% brownfield, and expects this capex spend to be completed by FY27. The stated focus is on capacity expansion for existing APIs, building capacities for the new API pipeline, and land acquisition for a greenfield project.

Importantly, the company explicitly links this capex cycle to returns. It states that the current round of capex is targeted to deliver returns in the high-teens range. Alongside, it has set an operational goal: improving average net asset turnover from 1.36 currently to 1.75 over the next 2 to 3 years. The key drivers cited include becoming the number 1 player globally in anti-inflammatory, generating additional revenues through its arrangement with Chemo, and market share wins in other APIs.

What to watch

The presentation makes a strong case for a margin-focused model, driven by product mix and R and D-led process optimisation. It cites structural gross margin expansion across cycles and notes stable gross margins despite price erosion, supported by new product development, 35 plus process patents, and partnerships such as a JV with Cemo Iberica S.A.

At the same time, there are a few monitoring points. Q1 FY27 revenue was lower sequentially versus Q4 FY26. Finance costs increased in FY26 versus FY25, which matters in a capex-heavy period. And the presentation uses multiple gross margin definitions across slides, so investors should track the underlying basis consistently in future disclosures.

Overall, Q1 FY27 reflects a company that is maintaining profitability while pushing forward on filings, capacity build-out, and an R and D scale-up that extends into peptides. The next few quarters should clarify how quickly the capex program converts into higher utilisation and whether the targeted increase in asset turnover begins to show up in reported numbers.